RxDoctor Payments DataLook up a doctor →

Praful Ravi

Medical Oncology · Boston, MANPI 1528447703

Payments from drug & device makers

$7,434,420in general payments, 2019–2025

Across 58 payments — averaging $128,180 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$7.2M
  • Blue Earth Diagnostics$177K
  • AstraZeneca$47K
  • Johnson & Johnson$3K
  • Bayer$2K
  • Genentech, Inc.$576
  • plus $686 from 3 others
$919,639in research payments, 2019–2025

Across 2 payments — averaging $459,820 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lilly USA, LLC$920K

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,434,420 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$51,623
Medicare patients
230
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →